These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9646097)

  • 1. [An alternative hypothesis of the pathogenesis of atherosclerosis].
    Bhakdi S
    Herz; 1998 May; 23(3):163-7. PubMed ID: 9646097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion.
    Torzewski M; Klouche M; Hock J; Messner M; Dorweiler B; Torzewski J; Gabbert HE; Bhakdi S
    Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):369-78. PubMed ID: 9514405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.
    Bhakdi S; Dorweiler B; Kirchmann R; Torzewski J; Weise E; Tranum-Jensen J; Walev I; Wieland E
    J Exp Med; 1995 Dec; 182(6):1959-71. PubMed ID: 7500042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits.
    Schmiedt W; Kinscherf R; Deigner HP; Kamencic H; Nauen O; Kilo J; Oelert H; Metz J; Bhakdi S
    Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1790-5. PubMed ID: 9812919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement and atherogenesis: the unknown connection.
    Bhakdi S
    Ann Med; 1998 Dec; 30(6):503-7. PubMed ID: 9920350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis.
    Torzewski M; Suriyaphol P; Paprotka K; Spath L; Ochsenhirt V; Schmitt A; Han SR; Husmann M; Gerl VB; Bhakdi S; Lackner KJ
    Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2130-6. PubMed ID: 15345515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages.
    Klouche M; Gottschling S; Gerl V; Hell W; Husmann M; Dorweiler B; Messner M; Bhakdi S
    Arterioscler Thromb Vasc Biol; 1998 Sep; 18(9):1376-85. PubMed ID: 9743225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection.
    Torzewski M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond cholesterol: the enigma of atherosclerosis revisited.
    Bhakdi S; Lackner KJ; Han SR; Torzewski M; Husmann M
    Thromb Haemost; 2004 Apr; 91(4):639-45. PubMed ID: 15045123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Malik TH; Cortini A; Carassiti D; Boyle JJ; Haskard DO; Botto M
    Circulation; 2010 Nov; 122(19):1948-56. PubMed ID: 20974996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory reactions in the pathogenesis of atherosclerosis.
    Fan J; Watanabe T
    J Atheroscler Thromb; 2003; 10(2):63-71. PubMed ID: 12740479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of atherosclerosis: infectious versus immune pathogenesis. A new concept.
    Bhakdi S
    Herz; 2000 Mar; 25(2):84-6. PubMed ID: 10829244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins.
    Malle E; Waeg G; Schreiber R; Gröne EF; Sattler W; Gröne HJ
    Eur J Biochem; 2000 Jul; 267(14):4495-503. PubMed ID: 10880973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation and progression of atherosclerosis--enzymatic or oxidative modification of low-density lipoprotein?
    Torzewski M; Lackner KJ
    Clin Chem Lab Med; 2006; 44(12):1389-94. PubMed ID: 17163812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence.
    Bhakdi S; Torzewski M; Paprotka K; Schmitt S; Barsoom H; Suriyaphol P; Han SR; Lackner KJ; Husmann M
    Circulation; 2004 Apr; 109(15):1870-6. PubMed ID: 15037531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathogenesis of atherosclerosis: an overview.
    Schwartz CJ; Valente AJ; Sprague EA; Kelley JL; Nerem RM
    Clin Cardiol; 1991 Feb; 14(2 Suppl 1):I1-16. PubMed ID: 2044253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].
    Yoshida H
    Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis.
    Ylä-Herttuala S
    Ann Med; 1991; 23(5):561-7. PubMed ID: 1721825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation by oxidatively modified low-density lipoproteins.
    Wieland E; Dorweiler B; Bonitz U; Lieser S; Walev I; Bhakdi S
    Eur J Clin Invest; 1999 Oct; 29(10):835-41. PubMed ID: 10583425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.